Results 151 to 160 of about 316,892 (282)

SynNER: syntax-infused named entity recognition in the biomedical domain. [PDF]

JAMIA Open
Imran M, Zamaraeva O, Gómez-Rodríguez C.   +2 more
europepmc   +1 more source

Developing a critical caste analysis within information science and technology: A research review: An annual review of information science and technology paper

Journal of the Association for Information Science and Technology, EarlyView.
Abstract Caste—an ascriptive social hierarchy in South Asia and its diaspora—is a globalized phenomenon. Recent caste‐based discrimination, particularly in technology companies and anti‐caste efforts to address it, has compelled academia, policy, and the technology industry to better understand contemporary mechanics of caste.
Nayana Kirasur, Britt Paris
wiley   +1 more source

A Chinese Named Entity Recognition Dataset for Intangible Cultural Heritage. [PDF]

Sci Data
Long S, Li W.
europepmc   +1 more source

CTP Ontology: A Semantic Model for Structuring Cultural Thematic Paths

Journal of the Association for Information Science and Technology, EarlyView.
Abstract A thematic path enhances the appreciation of cultural heritage by connecting diverse cultural objects through shared themes. This study introduces the Cultural Thematic Path (CTP) Ontology, designed to support the creation, organization, description, publication, and management of thematic paths within the GLAM (Galleries, Libraries, Archives,
Tiziana Pasciuto, Riccardo Albertoni, Roberta Maggi   +2 more
wiley   +1 more source

Enhancing Named Entity Recognition for immunology and immune-mediated disorders. [PDF]

Front Immunol
Chen S, Che J, Sun M, Wang Y.
europepmc   +1 more source

Optimization of pharmaceutical research and development by early‐phase assessment of investigational medicinal products

British Journal of Clinical Pharmacology, EarlyView.
Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló, Attila Imre, Gábor Varga, Sándor Kovács, György Tímár, Balázs Nagy   +5 more
wiley   +1 more source

ANCHOLIK-NER: A benchmark dataset for Bangla regional named entity recognition. [PDF]

PLoS One
Paul B, Preotee FF, Sarker S, Refat SR, Islam S, Muhammad T, Hoque MA, Manzoor S.   +7 more
europepmc   +1 more source

Do drugs approved via expedited approval pathways have therapeutic advantages? A systematic review and meta‐analysis

British Journal of Clinical Pharmacology, EarlyView.
Regulators use expedited approval pathways to speed market approval and patient access to promising new drugs. However, there is uncertainty about whether these pathways are successful in approving drugs with significant therapeutic advantages. This systematic review aims to examine the safety, effectiveness and cost‐effectiveness of drugs approved via
Ashleigh Hooimeyer, Eliza J. McEwin, Zhicheng Wang, Joel Lexchin, Barbara Mintzes   +4 more
wiley   +1 more source

Leveraging large language models for rare disease named entity recognition. [PDF]

PLOS Digit Health
Xi NM, Deng Y, Wang L.
europepmc   +1 more source

The evolving therapeutic landscape of spinal muscular atrophy – A scoping review of investigational agents, emerging delivery technologies and strategic innovations

British Journal of Clinical Pharmacology, EarlyView.
Spinal muscular atrophy (SMA) is a severe neuromuscular disease with emerging therapeutic complexity. This review aims to systematically map the global pipeline of investigational treatments for SMA. Using ClinicalTrials.gov and complementary international registries, we identified 21 planned or ongoing interventional trials from 2020 to 2025 targeting
Andrej Belančić, Patrick Eustaquio, Elvira Meni Maria Gkrinia, Ivana Stević, Eugen Javor, Yun Wah Lam, Slobodan Janković, Dinko Vitezić   +7 more
wiley   +1 more source